Clinical trials: Dapagliflozin
Chronic Kidney Disease
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin…
- Trial name
- NCT07450820
- Where
- Spain
- Volunteers
- 12,894 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with…
- Trial name
- NCT02433678
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University at Buffalo
End-stage Renal Disease
Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients
Sodium-glucose co-transporter 2 inhibitors (Sglt2i) attenuate the incidence of cardiovascular events in individuals with preserved or mildly reduced kidney function.
- Trial name
- DARE-ESKD 1 (NCT05343078)
- Testing
- Dapagliflozin 10Mg Tab
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- University of Campinas, Brazil
Heart Failure, Heart Valve Prosthesis
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
This study evaluates whether adding a medication called semaglutide to an existing treatment of dapagliflozin provides better outcomes for patients with heart failure who have previously undergone surgical heart valve…
- Trial name
- SYNCARDIA-HF (NCT07610174)
- Testing
- semaglutide, Dapagliflozin (10mg Tab)
- Where
- Egypt
- Volunteers
- 160 people
- Sponsor
- Kafrelsheikh University
Diabetes Mellitus, Type 2, Hyperglycemia
Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
This clinical trial investigates the effects of adding different diabetes medications to patients with type 2 diabetes who are currently being treated with DPP4 inhibitors.
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance
- Trial name
- NCT07108985
- Testing
- Sitagliptin 100 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with…
- Trial name
- NCT04255238
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg
- Volunteers
- 468 people
- Sponsor
- LG Chem
Glioma, Dapagliflozin (Forxiga)
Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients
The aim of the study is to compare between the role of dapagliflozin versus dexamethasone in pre-operative management of non-diabetic glioma patients on levetiracetam as anti-seizure drug.
- Conditions
- Glioma, Dapagliflozin (Forxiga), Dexamethasone
- Trial name
- NCT06750458
- Testing
- DexamethasoneGroup III (n=25) (Dexamethasone group)
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Tanta University
Heart Failure, Diabetes
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D)…
- Trial name
- NCT04249778
- Testing
- Dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Emory University
Functional Mitral Regurgitation
Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling
Functional mitral regurgitation (FMR) leads to various adverse outcomes. Cardiac remodeling (CR) and myocardial fibrosis (MF) are closely related to FMR, forming a vicious circle of CR-FMR-MF and resulting in the end-stage heart…
- Trial name
- DEFORM (NCT05606718)
- Testing
- Dapagliflozin, guideline-directed medical therapy (GDMT)
- Where
- 3 sites in China
- Volunteers
- 98 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes Mellitus
Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China
DONATE study is a multi-center, prospective cohort, single arm, observational study to be performed in 3000 Chinese type 2 diabetes mellitus (T2DM) patients recruited from 100 tier 2 or 3 hospitals, China.It is a drug intense…
- Trial name
- DONATE (NCT03156985)
- Where
- 83 sites in China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Acute Decompensated Heart Failure
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
National, multicenter, randomized, double-blind, parallel-group, stratified by SGLT-2 inhibitor type, placebo-controlled trial, - a Phase III study.
- Trial name
- EMPATHY (NCT05776043)
- Testing
- Empagliflozin 10 MG, Dapagliflozin 10 MG
- Where
- Poland
- Volunteers
- 1,364 people
- Sponsor
- Medical University of Warsaw
Pediatric Hereditary Kidney Diseases
The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children
This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children
- Trial name
- NCT06890143
- Testing
- Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Children's Hospital of Fudan University
Heart Failure, Systolic, Iron Deficiencies
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
Background. Treatment with intravenous iron has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency.
- Trial name
- COMBINED-HF (NCT06434025)
- Testing
- Iron Carboxymaltose, Dapagliflozin 10mg Tab
- Where
- Brazil
- Volunteers
- 99 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Type2Diabetes
Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients
The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with SGLT2-i in subjects with type 2 diabetes and older than 70 years in normal clinical practice.
- Trial name
- SOLDMiDiab02 (NCT05477017)
- Testing
- SGLT2 inhibitor
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- University of Milan
Type 2 Diabetes Mellitus
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be enrolled into the wash-out phase or directly into the…
- Trial name
- NCT02157298
- Testing
- Dapagliflozin 5 mg
- Where
- 14 sites in Japan
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²
This study was designed to compare empagliflozin and dapagliflozin in reducing protein leakage into the urine in adults with type 2 diabetes and chronic kidney disease.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Trial name
- NCT07866235
- Testing
- Dapagliflozin, Empagliflozin (EMPA)
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Lahore General Hospital
Cardiovascular Events, Type2 Diabetes
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose…
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Trial name
- CER-4-T2D (NCT05220917)
- Testing
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA
- Where
- United States
- Volunteers
- 781,430 people
- Sponsor
- Brigham and Women's Hospital
Type2 Diabetes, Remodeling, Ventricular
Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D); however, the underlying mechanism remains unclear.
- Trial name
- NCT05194592
- Testing
- Dapagliflozin, Gemigliptin
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- Wonju Severance Christian Hospital
Acute Myocardial Infarction With ST Elevation
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition.
- Trial name
- GALACTUS (NCT07295223)
- Testing
- Dapagliflozin 10 MG Oral Tablet, Semaglutide (Rybelsus®)
- Where
- Mexico
- Volunteers
- 44 people
- Sponsor
- Instituto Mexicano del Seguro Social
Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors
SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial
The goal of this clinical trial is to find out whether 12 months of treatment with the SGLT2 inhibitor Forxiga® (dapagliflozin 10 mg once daily), compared with placebo, can reduce the risk of developing post-transplant diabetes…
- Conditions
- Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial (RCT)
- Trial name
- SGL-TX-PTDM (NCT07682350)
- Testing
- SGLT2i
- Where
- 3 sites in Denmark
- Volunteers
- 184 people
- Sponsor
- Odense University Hospital